Generic Name and Formulations:
Somatropin (rDNA origin) 4mg, 5mg, 6mg; per vial; for SC inj after reconstitution.
EMD Serono, Inc.
Indications for SEROSTIM:
HIV patients with wasting or cachexia to increase lean body mass and weight, and improve physical endurance.
Give by SC inj once daily at bedtime. Rotate inj sites. <35kg: 0.1mg/kg. 35–45kg: 4mg. 45–55kg: 5mg. >55kg: 6mg. Risk factors for adverse effects (eg, glucose intolerance): initially 0.1mg/kg every other day.
Not established; see full labeling.
Acute critical illness due to surgical complications or multiple accidental trauma or those with acute respiratory failure. Active malignancy. Active proliferative or severe non-proliferative diabetic retinopathy.
Increased mortality in those with acute critical illness (see Contraindications). Use only under guidance of a physician trained in HIV management. HIV patients should be maintained on antiretroviral therapy. Glucose intolerance. Diabetes. Perform baseline and periodic funduscopic evaluation for intracranial hypertension; discontinue if papilledema occurs; may restart at lower dose after resolution. Monitor for development, progression, or recurrence of neoplasms. Discontinue if carpal tunnel syndrome persists after dosage reduction. Turner syndrome. Elderly. Pregnancy (Cat.B). Nursing mothers.
Growth hormone (GH).
May be antagonized by glucocorticoids. May affect CYP450 substrates (eg, corticosteroids, sex steroids, anticonvulsants, cyclosporine); monitor. Concomitant oral estrogens; may require larger somatropin doses. Concomitant insulin and/or hypoglycemics may require dose adjustment.
Musculoskeletal discomfort, increased tissue turgor, edema, nausea, fatigue, gynecomastia, paresthesia, hypoesthesia, hyperglycemia, hypertriglyceridemia, carpal tunnel syndrome; intracranial hypertension, serious hypersensitivity reactions; rare: pancreatitis.
Single-dose vials (5mg, 6mg)—7 (w. diluent); Multi-dose vials (4mg)—7 (w. diluent)
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies